

# MONTHLY UPDATE

April 2013

## Inside This Issue

### 1-2 Participation Opportunities

**IBA Members: Register to Attend IBA's 3<sup>rd</sup> Annual Golf Outing!**

Discovering Cures Iowa  
Network Forming to Promote and Expand Clinical Research in Iowa

### 2-4 New Member Spotlight

Johnson & Johnson  
Nyemaster Goode, P.C.

### 4-5 Upcoming Events

May 2013  
June 2013  
August 2013  
November 2013

### 5-7 Breaking News

Food & Agriculture  
Healthcare & Pharmaceutical  
Industrial & Environmental

### 7-8 In Other News

Iowa Demonstration Fund Performing Well

### 8 Subscriber Information & Speaker Opportunities

## Participation Opportunities

[\(Return to Index\)](#)

### IBA 3<sup>rd</sup> Annual Golf Outing

[\(Return to Index\)](#)



Iowa Biotech Association is excited to announce it will be hosting its 3<sup>rd</sup> Annual Golf Outing this June! This event is limited to Iowa Biotech Association members and affiliates. We hope to offer a great day of fun and relaxation, as well as opportunities to network with our generous event sponsors.

The outing will take place at [The Legacy Golf Club](#) in **Norwalk, Iowa** on **June 6, 2013**.

**Registration is free** and the event will include:

- A Continental Breakfast
- A Putting Contest and Expo
- 18 Holes of Golf
- Play-Through Lunch
- Contests, Prizes and Giveaways

More information, along with sponsorship opportunities, registration information, and photos from previous years, can be found at [www.iowabio.org/golf](http://www.iowabio.org/golf). **The registration deadline for this event is May 24<sup>th</sup>**. We hope to see you there!

###

# MONTHLY UPDATE

April 2013



## Discovering Cures Iowa – Save the Date!

[\(Return to Index\)](#)

Iowa Bio, Partnership for Better Health and Discovering Cures Iowa are excited to extend an open invitation to this educational meeting regarding biotech and patient advocacy issues relative to the state of Iowa. It will be a chance for attending members to engage in dialogue and understand how these issues affect their industry and research.

### Agenda

- **8:30-9:00** Registration and Breakfast
  - **9:00-10:00** Introductions and a Discussion Panel, Followed by a Q&A Session
- \*Discussion Panel speakers to be confirmed and posted at [www.iowabio.org/cures](http://www.iowabio.org/cures) soon!*

### Location

[Renaissance Des Moines Savery Hotel](#)

401 Locust Street  
Des Moines, IA 50309

*\*Public parking is available in the Fourth & Grand Parking Garage, located on Grand Avenue.*

If you are interested in attending this **FREE** event, please submit your registration at [www.iowabio.org/cures](http://www.iowabio.org/cures). If you have any questions, please contact us at [info@iowabio.org](mailto:info@iowabio.org) or 515.327.9156

###



## Network Forming to Promote and Expand Clinical Research in Iowa

[\(Return to Index\)](#)

Last September, the Iowa Biotech Association partnered with Innovate Iowa to release a report detailing more than 1,100 clinical trials that have taken place in Iowa since 1999. Clinical trials are responsible for 45 to 75 percent of the \$1.2 billion average cost of developing one new cutting-edge biotechnology medicine. In addition to contributing to local economies where trials are conducted, patients often benefit from excellent 1-on-1, access to medications that would otherwise be unavailable, and the opportunity to help future generations.

Given the positive media coverage surrounding the release of that report and the need to further educate the public about the opportunities that clinical trials present, a new network is being formed. **If you are involved in clinical research in Iowa and see value in collaborating with others to help raise the profile of clinical research** please contact Heidi Frederickson at [hfrederickson@pubaffairscs.com](mailto:hfrederickson@pubaffairscs.com) or 612-219-2837.

###

## New Member Spotlight

[\(Return to Index\)](#)

**Johnson & Johnson**

### Johnson & Johnson

[\(Return to Index\)](#)

Caring for the world, one person at a time: that's what inspires and unites the people of Johnson & Johnson. They embrace research and science -- bringing innovative ideas, products and services to advance the health and well-being of people throughout the world. Employees of the Johnson & Johnson Family of Companies work with partners in health care to touch the lives of more than a billion people every day.

The Johnson & Johnson Family of Companies comprises:

- The world's sixth-largest consumer health company
- The world's largest and most diverse medical devices and diagnostics company
- The world's fifth-largest biologics company
- And the world's eighth-largest pharmaceuticals company

Johnson & Johnson has played a role in helping people the world over be well and stay well through more than a century of change. As the science of human health and well-being has grown, Johnson & Johnson has been able to grow along with it. Even more important, we've been able to help shape and define what health and well-being means in everyday lives.

A vast array of products is offered through Johnson & Johnson businesses, which are grouped into Consumer, Medical Devices & Diagnostics, and Pharmaceutical segments. Whether analgesics or baby care, endoscopic

# MONTHLY UPDATE

April 2013

surgery or interventional cardiology, oral care or wound care, the Johnson & Johnson Family of Companies makes products that help people live healthier lives. Some examples of Johnson & Johnson products include:

## REMICADE®

REMICADE® (infliximab) is approved for 16 indications in the U.S. including ulcerative colitis (UC), in certain children, as well as adults. REMICADE® is approved for the treatment of other autoimmune diseases such as Crohn's disease in adults and children 6 years and older, as well as rheumatoid arthritis, ankylosing spondylitis (arthritis affecting the joints in the spine and the pelvis), psoriatic arthritis (joint pain associated with psoriasis), and plaque psoriasis in adults. REMICADE® belongs to a class of drugs called tumor necrosis factor (TNF) blockers. TNF blockers suppress the immune system by blocking the activity of TNF, a substance in the body that can cause inflammation and lead to autoimmune diseases. For safety information, please visit [www.REMICADE.com](http://www.REMICADE.com).

## INVOKANA™

INVOKANA™ (canagliflozin) is the first in a new class of medications called sodium glucose co-transporter 2 (SGLT2) inhibitors to be approved in the U.S. for the treatment of adults with type 2 diabetes. It is also the only oral, once-daily medication available in the U.S. offering improved blood sugar control while also showing reduced body weight and systolic blood pressure in clinical trials. INVOKANA™ works with the kidneys and the natural process of urination to help remove excess sugar. INVOKANA™ is used along with diet and exercise to improve blood sugar control in adults with type 2 diabetes. The most common adverse events with INVOKANA™ are genital mycotic (fungal) infections, urinary tract infections and increased urination. These specific adverse events are generally mild to moderate in intensity. For important safety information, please visit [www.INVOKANA.com](http://www.INVOKANA.com), and please see the full Product Information and Medication Guide.

## CARTO® 3 System

This cardiac mapping technology gives physicians a detailed three-dimensional view of the heart so they can treat cardiac arrhythmias, including atrial fibrillation. The CARTO® 3 System is just one of the latest innovations from Biosense Webster, the Johnson & Johnson company recognized worldwide as a leader in the science behind the diagnosis and treatment of cardiac arrhythmias.

## EVARREST™ Fibrin Sealant Patch

This product rapidly and reliably aids in stopping problematic bleeding during surgery. The patch consists of a

coating of human thrombin and fibrinogen, which react to initiate a fibrin clot. This then integrates into the patch providing mechanical support and adherence to the wound site. Unexpected and uncontrollable bleeding during surgery poses a significant challenge, and in some surgical procedures can raise the patient's mortality rate to 20%.

## Consumer Products

Our Consumer segment includes a broad range of products, including our iconic Johnson's® brand baby products, skin care, oral care, wound care and women's health care fields, as well as nutritional and over-the-counter pharmaceutical products, and wellness and prevention platforms.

Johnson & Johnson has more than 275 operating companies in more than 60 countries employing nearly 128,000 people. The worldwide headquarters is located in New Brunswick, New Jersey. For more information about Johnson & Johnson, their services and products, please contact Susan Zalenski at [szalensk@its.jnj.com](mailto:szalensk@its.jnj.com) or 913-592-2675.

###

**NYEMASTER**  
NYEMASTER GOODE PC  
**Nyemaster Goode, P.C.**

[\(Return to Index\)](#)

Founded in 1918, Nyemaster Goode is Iowa's largest law firm, with offices in Des Moines, Ames, and Cedar Rapids. Nyemaster's broadly diverse practice enables its attorneys to offer solutions to the most challenging legal issues in virtually every area of the law, to companies that range in size from emerging start-ups to *Fortune* 500s, as well as to individuals. Nyemaster Goode's attorneys are consistently recognized in *The Best Lawyers in America*, *Chambers USA*, *America's Leading Lawyers for Business*, and *Great Plains' Super Lawyers*.

Nyemaster Goode's attorneys strive to provide our clients with fast, professional, and cost-effective legal representation. The firm offers legal services to clients through six primary departments: Business, Finance, and Real Estate; Governmental Affairs; Intellectual Property; Labor and Employment; Litigation; and Tax, Estate Planning, and Employee Benefits.

Nyemaster Goode's intellectual property attorneys have experience in a wide range of intellectual property matters, including patents, trademarks, copyrights, trade secrets and

# MONTHLY UPDATE

April 2013

related licensing, transactional due diligence and litigation. Attorney services include patent and trademark prosecution, maintenance, and enforcement in the U.S. and throughout the world. Nyemaster attorneys also have experience in many Internet and e-commerce matters, including domain name disputes, website development and regulatory compliance. Intellectual property issues arise in a variety of situations, from business acquisitions and licensing agreements to litigated infringement actions, and the diversity of our attorneys' experience coupled with our multidisciplinary practice areas allows Nyemaster to assist clients with these complex and important intellectual property matters.

Nyemaster Goode has one of the largest and broadest transactional practices in Iowa. Its corporate attorneys advise public, private, and family-owned businesses, handling all types of business and commercial transactions. The attorneys in the governmental affairs department represent clients before the Iowa Legislature, the Governor's office, state agencies, and governmental subdivisions, ensuring that its clients' voices are heard at all levels of government. Nyemaster's labor and employment attorneys help clients negotiate the wide spectrum of laws governing the workplace. Nyemaster attorneys partner with clients to gain and maintain a competitive edge in handling labor and employment issues, and offer experience across a broad spectrum of litigation. Nyemaster's trial attorneys have been widely recognized for their abilities to handle clients' critical litigation matters. Nyemaster also has a large tax law practice, and its tax attorneys strive to deliver a broad range of tax-related services, such as advising clients in estate planning and administration, employee benefits, tax controversies, and a variety of transactional tax planning matters.

Wendy K. Marsh, Shareholder and Registered Patent Attorney  
515.645.5502  
[wkmarsh@nyemaster.com](mailto:wkmarsh@nyemaster.com)  
[www.nyemaster.com](http://www.nyemaster.com)

###

## Upcoming Events

[\(Return to Index\)](#)

*Per reader feedback, we have updated this section to only include 1) events around the Midwest and 2) events IBA is hosting and/or attending. A full listing of industry events can be viewed on our online [Events Calendar](#).*

### [lowAsia Business Summit](#)

May 10, 2013 / West Des Moines, IA

In its third year, the lowAsia Business Summit brings together strategic partners to facilitate business and investment opportunities between Iowa and Asia. IAA has worked with member Asian community associations to bring their Consuls General to the event as well as with the Iowa Economic Development Authority to invite Iowa businesses interested in exploring, establishing, or expanding business relationships in Asia. Foreign dignitaries and Iowa business leaders will also have an opportunity to visit with Governor Terry Branstad and Lt. Governor Kim Reynolds about current and potential state resources that can enhance the already strong ties between Iowa and Asia.

[\(Return to Index\)](#)

### [Discovering Cures Discussion Panel](#)

June 7, 2013 / Des Moines, IA

Iowa Bio, Partnership for Better Health and Discovering Cures Iowa are excited to extend an open invitation to this educational meeting regarding biotech and patient advocacy issues relative to the state of Iowa. It will be a chance for attending members to engage in dialogue and understand how these issues affect their industry and research.

Please visit [www.iowabio.org/cures](http://www.iowabio.org/cures) for more information and registration details.

[\(Return to Index\)](#)

### [2013 BIO World Congress](#)

June 16-19, 2013 / Montréal, Canada

The BIO World Congress on Industrial Biotechnology is the world's largest industrial biotechnology event for business leaders, investors and policy makers in biofuels, biobased products, and renewable chemicals. Entering its tenth year, BIO World Congress offers unique networking opportunities, an overview of the latest technological developments and real world scenarios for bringing

# MONTHLY UPDATE

April 2013

technological solutions to market. The event features discussions of high profile topics related to sustainability, new sources of fuel, climate change, financing, and policy.

**Money Saving Opportunity!** – Export Trade Assistance Program (ETAP) funds are a great way to receive financial assistance to attend this event. The application date has been extended to **September 30, 2013**. [By clicking here](#), you will find information on how to apply, as well as on other financial assistance opportunities such as the Domestic Trade Assistance Program and State Export Trade Assistance program.  
([Return to Index](#))

## [5th Annual Animal Health Investment Forum](#)

August 27, 2013 / Kansas City, MO

The KC Animal Health Investment Forum provides a unique opportunity for venture capital funds, investment firms and animal health companies to hear from emerging companies with the newest technology. The event offers one of the only opportunities in the world for early stage companies in the animal health sector to present their vision and business plan to potential investors. Companies presenting at the Forum have raised nearly \$85 million. Several have also received licensing agreements or distribution contracts.  
([Return to Index](#))

## [Drug Development Boot Camp 2013](#)

November 20-21, 2013 / Boston, MA

**\$50 Discount Available for Iowa Bio Members** - The Drug Development Boot Camp is a unique, intensive, integrated drug development training which immerses the participants in drug development using a unique approach pioneered by Dr. Lorna Speid. A world quality expert Faculty that have worked together to develop the Boot Camp materials will teach the Boot Camp. Not only will you have fun at the Boot Camp, but you will be totally immersed in the principles of drug development for two days, allowing you to take your drug development skills to another level.

**IBA Members:** To receive your \$50 discount and attend this event, please email Lorna Speid at [lspeid@sndtm.com](mailto:lspeid@sndtm.com) and copy [melissa@iowabio.org](mailto:melissa@iowabio.org).  
([Return to Index](#))

###

## Breaking News

([Return to Index](#))

## Food & Agriculture

([Return to Index](#))



- ✔ **Bayer** starts construction of **Tennessee R&D plant**
- ✔ **Bayer** teams up with **KeyGene** to enhance **crop traits**



- ✔ **Dow, Monsanto** sign **corn technology cross-licensing deal**
- ✔ **Paraguayan** farmers indicate **agreement with Monsanto**
- ✔ **Biotech rider** only codifies existing case law, **USDA practice**
- ✔ Some U.S. farming groups want to **extend biotech rider**
- ✔ **European Union's biotech crop policies** are unnecessary, **USTR** says
- ✔ Supermarket's **biotech labeling initiative** spreads **misperception**
- ✔ Developing countries need **biotech foods**
- ✔ **Biotech food policies** should be based on scientific data
- ✔ **Biotech crop-makers** to launch **campaign against labeling drive**
- ✔ **Dow's biotech research facility** inaugurated in **Indiana**
- ✔ Biotech crop company **AgBiome** gets **\$14.5M funding boost**

# MONTHLY UPDATE

April 2013

- ✔ **'Gene-editing'** expected to develop **disease-resistant breeds**
- ✔ **New cowpea varieties** offer promise in South Africa, other parts of the world
- ✔ **Genetically engineered salmon** company expects U.S. regulatory OK in 2013

###

## Healthcare & Pharmaceutical

[\(Return to Index\)](#)



- ✔ **Benchmark Biolabs** and **AgriLabs** Jointly Form **VaxLiant** to Offer Innovative **Vaccine Adjuvants**



- ✔ **First US Patent for Vaccine Treatment of Obesity** Is Awarded to **Braasch Biotech LLC**



- ✔ **New BIO Chairwoman: Biotechnology** has proud story to tell



- ✔ **J&J's** first-in-class **Invokana** gets FDA OK for **type 2 diabetes**



- ✔ **Thermo Fisher** boosts sequencing business with \$13.6B **Life Technologies** buy
- ✔ **Midwest region** emerging as **top biotech hub spots**
- ✔ Researchers track **evolution of HIV antibody**
- ✔ **VaxInnate** wins \$2.2M NIAID grant to **develop dengue vaccine**
- ✔ Seven **New Obesity Genes** Identified

- ✔ **Genome Study** Offers Hints to **Unusual Traits in Platyfish**

- ✔ FDA approves midstage study of **BioLineRx's leukemia drug**

- ✔ FDA permits **Acadia** to file **NDA for psychosis drug** without additional trial

- ✔ **Merck** licenses **West Nile vaccine technology rights** to Hawaii Biotech

- ✔ **FDA** would get **\$821M boost** under **HHS budget proposal** for 2014

- ✔ **Bioengineered kidneys** could lead to creation of replacement organs

- ✔ **Bristol, Santaris** to develop **RNA drugs** in deal with \$100M potential

- ✔ **Stem cells from bone marrow** do well in Mayo heart failure trial

- ✔ **Exact Sciences'** Noninvasive **Colorectal Cancer Test** Proves True

- ✔ EU approves **Sanofi's 6-in-1 vaccine for infants**

- ✔ **Twin Study** Indicates Role for **DNA Methylation in Autism Spectrum Disorders**

- ✔ **Merck's** **lambrolizumab** wins breakthrough status for **melanoma**

- ✔ **DecImmune** partners with **DSM** to develop **antibody drugs**

- ✔ Oncologists: **Prices of cancer drugs** must come down

###

## Industrial & Environmental

[\(Return to Index\)](#)



The miracles of science™

- ✔ **DuPont, USDA** team up for **sustainable corn-stover** collection

# MONTHLY UPDATE

April 2013

- ❖ **Biodiesel** use more than **triples in Iowa**
- ❖ **REG** releases white paper promoting **food security side of biodiesel**
- ❖ A New Use for **Algae**
- ❖ Study points to **emissions-free** production of **hydrogen fuel**
- ❖ Filing **deadline for biodiesel mixture payments** is moved to **July 1**
- ❖ 7 Steps to **meeting US renewable fuels targets**
- ❖ A crash of **algae, bioterrorism** and the **future of biofuels**
- ❖ **Abengoa** switches on **demo waste-to-fuel plant** in **Spain**
- ❖ EIA: **E85 use grew** 52% from 2010 to 2011
- ❖ **Colorado** to offer \$3.1 million in tax credits for **Cool Planet HQ**
- ❖ **Sweetwater, Naturally Scientific** ink \$250M pact for **biobased sugars**
- ❖ **Joule reports progress** in scaling up of **advanced biofuels process**
- ❖ Report: U.S. leads in **cellulosic ethanol production**
- ❖ Who killed **\$2.18 gasoline?**
- ❖ Two **Iowa-based advanced biofuel firms** get \$10.6M boost from feds
- ❖ **Dyadic Talks Enzyme Production for Biofuels** at ABLC
- ❖ **Minnesota bill** would allow **other biofuels to meet ethanol mandate**
- ❖ **New synthetic biofuel** could replace diesel and jet fuel

###

## In Other News...

[\(Return to Index\)](#)

### Iowa Demonstration Fund Performing Well

[\(Return to Index\)](#)

Article by Rod Boshart

An effort to help start-up businesses survive and thrive started under the Culver administration got rave reviews Monday from Gov. Terry Branstad and his economic development helpers.

Results of a study on the economic and fiscal impact of the state's demonstration fund found the \$8.7 million and technical assistance provided to 79 companies between 2007 and 2011 to encourage high technology prototype and concept development activities created 600 new jobs and generated \$2.1 million in new tax revenue.

- [VIEW THE FULL REPORT](#)

Chris Nelson, president and CEO of Kemin Industries and board member of the Iowa Innovation Corporation – which oversees the fund – said the return on the state's investment averaged about 24 percent.

"I'll take that any day," Nelson told a Statehouse news conference discussing the study results. He said \$13 million was awarded to 110 companies since the fund was initiated and 101 of those awardees are still in existence.

The Demonstration Fund supports commercialization activities by small and medium-sized Iowa companies in the advanced manufacturing, biosciences, and information technology industries, state officials said. The primary purpose of the fund is to help businesses with a high-growth potential reach a position where they are able to attract later stage private sector funding in hopes of achieving commercially viable products or services within a reasonable period of time.

"The success of the Demonstration Fund was the result of dedicated and motivated industry leaders from across Iowa whose vision was to grow the innovation economy by investing and mentoring emerging tech-based companies," Nelson said.

# MONTHLY UPDATE

April 2013

“Those of us involved with the applicants soon learned that the real value was the mentoring with the dollars being a close second,” he added. “Each recipient was asked to provide confidential feedback to the (Iowa Economic Development Authority) which confirmed our belief.”

Branstad said his administration is “perfecting and improving” a plan launched under former Gov. Chet Culver’s guidance, and IEDA Director Debi Durham said the Branstad administration has asked for \$2 million in fiscal 2014 to further fund innovative concepts.

The Demonstration Fund supports commercialization activities by small- and medium-sized Iowa companies in the advanced manufacturing, biosciences, and information technology industries. The primary purpose of the fund is to help businesses with a high-growth potential reach a position where they are able to attract later stage private sector funding.

“It is essential that we have tools in place to help Iowa’s high-growth, innovation-based companies succeed in our state,” Branstad said. “The Demo Fund is one way we have to do that and because of this report, we know quantifiably that the state is seeing a return on that investment.”

The creation of the Demonstration Fund was an outcome of the Iowa Innovation Council, an industry-led group that develops strategies and long-term plans to ensure that Iowa remains globally competitive in innovation-based enterprises. The Iowa Innovation Corp., a private non-profit organization created by the Iowa Innovation Council, has implemented a campaign to expand the success of companies, like the Demonstration Fund recipients, by fostering partnerships to create a statewide sustainable innovation network and advocating for ongoing innovation-based resources to grow Iowa’s economy.

Officials said the [Iowa Demonstration Fund Combined Economic and Fiscal Impact study](#) was a third-party review intended to quantify the impact of the Demonstration Fund on the Iowa economy. The report was authored by Econosult Solutions Inc. and was commissioned by the Iowa Innovation Corporation in partnership with the Iowa Economic Development Authority and the Iowa Innovation Council.

###

## Subscriber Information

[\(Return to Index\)](#)

This message was sent to you as a benefit of membership in the IBA and/or a subscriber of our monthly newsletter. If you know of a company that would benefit from the Association’s advocacy, financial savings and education/workforce focus, please have them contact the Association at 515-327-9156 or email [rachelhurley@iowabio.org](mailto:rachelhurley@iowabio.org). Membership details are also available at [www.iowabio.org](http://www.iowabio.org).

If you would like more information on any topic or no longer wish to receive these messages, please email [melissa@iowabio.org](mailto:melissa@iowabio.org) or call 515-494-9242.

###

## Speaker Opportunities

[\(Return to Index\)](#)

IBA staff members are available to give 15-60 minute speeches to interested groups, such as Rotary Clubs, trade associations, or civic groups. A broad range of topics could be discussed, including biotechnology, healthcare, food vs. fuel, legislative policy, investment and more. Contact Rachel Hurley at (515) 327-9156 or [rachelhurley@iowabio.org](mailto:rachelhurley@iowabio.org).